Pioneering fully individualized TCR therapies for cancer
Our Mission
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.
Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.
Cancer is a genetically individual disease – no two tumors are exactly the same. These variations create neoantigens – unique targets for every tumor. Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications.
While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers.
We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.
Carsten Linnemann, Ph.D., Chief Executive Officer
Our History
Neogene is built on the premise of innovation and novel paradigm-changing science to enable effective T-cell therapy of solid cancers.
-
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
- May 2019
-
September 2020
Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.
- October 2020
- September 2018
- September 2020
-
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
- May 2021
-
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
- May 2019
-
September 2020
Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.
- October 2020
- September 2018
- September 2020
-
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
- May 2021
Our Team
Neogene’s leadership team is comprised of world-leading TCR experts and cell therapy industry veterans with decades of oncology knowledge and experience, who hold a deep commitment to providing innovative therapies to patients with cancer.
Carsten Linnemann, Ph.D.
Chief Executive Officer
Brent Pfeiffenberger, Pharm.D., MBA
Chief Operating Officer
Jan J.H. Joosten
General Counsel
Han Lee, Ph.D.
Chief Financial Officer
Christopher Wilfong, MBA
Chief Business Officer
Sean Algeo, CPA
Treasurer and Corporate Controller
David M. Tanen
Corporate Secretary
Mauro P. Avanzi, M.D., Ph.D.
Vice President, Clinical Development
Gavin M. Bendle, Ph.D.
Vice President, Research and Development
Arianne Perez Garcia, Ph.D.
Vice President, Translational Sciences
Stephanie Heintz, M.P.H
Executive Director, Head of Human Resources
Marisa Leonard
Vice President, Head of Business Development
David Lund, Ph.D.
Vice President, Intellectual Property
Harish Mundre
Vice President, Head of Information Technology
Kanti Thirumoorthy, Ph.D.
Vice President, Technical Operations
